The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: A systematic review of economic evaluations

Applied Health Economics and Health Policy

Volumn 11, Issue 2, 2013, Pages 95-106

  Achilla, Evanthia ^a   McCrone, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; EMBASE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MEDLINE; PSYCINFO; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; ECONOMICS, PHARMACEUTICAL; HUMANS; SCHIZOPHRENIA; SLOVENIA;

EID: 84877010165     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0016-2     Document Type: Review

References (58)

1. World Health Organization (WHO). The global burden of disease: 2004 update. 2008 [online]. http://www.who.int/healthinfo/global-burden-disease/ estimates-regional/en/index.html. Accessed 15 May 2012.
2. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
3. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13.
4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279-93.
5. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161(Suppl. 2):1-56.
6. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-87.
7. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361(9369):1581-9.
8. National Institute for Health and Clinical Excellence (NICE). National Clinical Guideline 82 on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care [updated edition 2009]. http://publications.nice.org.uk/schizophrenia-cg82. Accessed 15 Apr 2012.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
10. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346-51.
11. Joyce AT, Harrison DJ, Loebel AD, et al. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care. 2005;11(Suppl. 8):s254-61.
12. Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11(7):1007-21.
13. Moore DB, Kelly DL, Sherr JD, et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm. 1998;55(Suppl. 4):s17-9.
14. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics. 2005;23(Suppl. 1):3-16.
15. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother. 2009;9(1):9-31.
16. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-7.
17. Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics. 2005;23(Suppl. 1):62-74.
18. Oh PI, Lanctot KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137-56.
19. Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Pharmacoeconomics. 2005;23(Suppl. 1):1-2.
20. Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3(1):2007-39.
21. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry. 2009;52:s29-36.
22. Bartko G, Feher L. Pharmacoeconomic review of the use of injectable long-acting risperidone [Hungarian]. Neuropsychopharmacol Hung. 2005;7(4):199-207.
23. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87-92.
24. Curran MP, Keating GM. Management of schizophrenia: defining the role of long-acting injectable risperidone. Dis Manag Health Outcomes. 2006;14(2):107-25.
25. Harrison TS, Goa KL. Spotlight on long-acting risperidone in schizophrenia. Am J Drug Deliv. 2004;2(3):L207-10.
26. Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm. 2004;61:1792-800.
27. Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2011;9(1):54.
28. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(Suppl. 1):35-47.
29. Hensen M, Heeg B, Lthgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327-41.
30. Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23:49-61.
31. Llorca PM, Miadi-Fargier H, Lancon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation [French]. Encephale. 2005;31(2):235-46.
32. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59(4):385-94.
33. Edwards NC, Rupnow MFT, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics. 2005;23(3):299-314.
34. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(Suppl. 1):75-89.
35. Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(Suppl. 3):66-9.
36. Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin. 2008;24(2):349-58.
37. Mantovani LG, Berto P, D' Ausilio A, et al. Costs and effects of Long Acting Risperidone (LAR) versus atypical antipsychotics in the treatment of schizophrenic subjects in Italy. Farmeconomia e percorsi terapeutici 2004;5(1):5-11.
38. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61(12):1979-88.
39. Baca E, Bobes J, Canas F, et al. Cost-effectiveness analysis of long-acting injectable risperidone v. olanzapine and v. fluphenazine decanoate in treating schizophrenia [Spanish]. Rev Esp Econ Salud 2005; 4(5):273-85.
40. Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics. 2008;26(4):341-58.
41. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011;27(4):713-30.
42. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin. 2008;24(12):3341-55.
43. Garcia-Ruiz AJ, Perez-Costillias L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2(1):8.
44. Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry. 2008;7(16):1-12.
45. Barnett PG, Scott JY, Rosenheck RA. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res. 2011;130:34-9.
46. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Act Psychiatr Scand. 2007;116:36-46.
47. Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone: a report of resource utilisation and costs in a 12 month mirror-image analysis. Clin Drug Investig. 2010;30(11):777-87.
48. Chang HC, Tang CH, Huang ST, McCrone P, Su KP. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751-6.
49. Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14(1):53-62.
50. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Act Psychiatr Scand. 2006;114(1):14-20.
51. Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41-53.
52. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Act Psychiatr Scanda. 2009;120(2):97-101.
53. Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997;171:509-18.
54. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004;13(11):811-6.
55. Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin. 2009;25(9):2197-206.
56. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(Suppl. 5):15-8.
57. Ginnelly L, Manca A. The use of decision models in mental health economic evaluation: challenges and opportunities. Appl Health Econ Health Policy. 2003;2(3):157-64.
58. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med. 2009;6(7):1-28.